Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

Annals of Neurology

Volumn 59, Issue 2, 2006, Pages 344-352

  Río, Jordi ^a,b   Nos, Carlos ^a   Tintoré, Mar ^a   Téllez, Nieves ^a   Galán, Ingrid ^a   Pelayo, Raúl ^a   Comabella, Manuel ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE;

ACCURACY; ADULT; ARTICLE; DEMOGRAPHY; DISABILITY; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; ROC CURVE; SENSITIVITY AND SPECIFICITY; SPAIN; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADULT; DEMOGRAPHY; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME;

EID: 32044463386     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20740     Document Type: Article

References (30)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular Interferon β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
3. PRIMS Study Group. Randomised double-blind placebo-controlled study of Interferon β-1a in relapsing-remitting multiple sclerosis. Lancet 1998;352:1498-1504.
4. Paty DW, Li DK, for the University of British Columbia MS/MRI Study Group and the IFN-β Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
5. Simon JH, Jacobs LD, Campion M, et al. for the Multiple Sclerosis Collaborative Research Group. Magnetic resonance studies of intramuscular interferon β-1a for the relapsing multiple sclerosis. Ann Neurol 1998;43:79-87.
6. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999;46:197-206.
7. Fusco C, Andreone V, Coppola G, et al. HLA-DRB1* 1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology 2001;57:1976-1979.
8. Kappos L, Polman C, Pozzilli C, et al. Final analysis of the European multicenter trial on IFNB-1b in secondary progressive MS. Neurology 2001;57:1969-1975.
9. Kracke A, von Wussow P, Al-Masri A, et al. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology 2000;54:193-199.
10. Rio J, Nos C, Tintore M, et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting MS patients treated with interferon beta. Implications for clinical trials. Ann Neural 2002;52:400-406.
11. Stürzebecher S, Wandinger KP, Rosenwald A, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003;126:1419-1429.
12. Villoslada P, Oksenberg JR, Rio J, Montalban X. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2004;62:1653.
13. Wandinger KP, Lunemann JD, Wengert O, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003;361:2036-2043.
14. Waubant E, Vukosic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003;61:184-189.
15. Petzold A, Brassat D, Mas P, et al. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis. Mult Scler 2004;10:281-283.
16. Rudick R, Lee J, Simon J, et al. Defining interferon β response status in multiple sclerosis patients. Ann Neurol 2004;56:548-555.
17. Baranzini SE, Mousavi P, Rio J, et al. Transcription-based prediction of response to IFN beta using supervised computational methods. PloS Biol 2005;3:e2.
18. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 1989;112:133-146.
19. Efron B, Tibshirani R. An introduction to bootstrap. New York: Chapman & Hall, 1993.
20. Altman DG, Machin D, Bryant TN, Gardner MJ, editors. Statistics with confidence. 2nd ed. London: BMJ Books, 2000.
21. Weinshenker BG, Issa M, Baskerville J. Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology 1996;46:1613-1619.
22. Weinshenker BG, Rice GPA, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991;114:1057-1067.
23. Weinshenker BG, Rice GPA, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045-1056.
24. Cohen BA, Khan O, Jeffery DR, et al. Identifying and treating patients with suboptimal responses. Neurology 2004;63(suppl 6):S33-S40.
25. Roullet E, Fez D, Le Canuet et al. Application of different criteria for clinical response to beta-interferon in relapsing-remitting MS. Neurology 2003;60(suppl 1):A168.
26. Cree BC, Goodin D, Oksenberg JR, et al. Multiple sclerosis disease activity in patients with different ethnic origin: data from the EVIDENCE trial. Neurology 2003;60(suppl 1):A61.
27. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419-1428.
28. Confavreux C, Vukosic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Eng J Med 2000;343:1430-1438.
29. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
30. Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 2004;62:2031-2037.